Start here if you're new
what it is
Legence designs, installs, and maintains the guts inside complex buildings that cannot afford to fail.
how it gets paid
Nine months ended Sep 30, 2025 revenue was ~$1.81B (+~17% vs. prior year). In Q3 2025, Installation & Maintenance was ~70% of revenue (~$496M of ~$708M).
why growth slowed (GAAP)
Interest, amortization, IPO-related costs, and tax line items can leave GAAP net negative even when operations generate cash — nine-month net loss attributable to Legence was ~$(27)M on ~$1.81B revenue (~−1.5% margin).
what just happened
Q3 2025: revenue ~$708M; GAAP diluted EPS ~$(0.02); consolidated gross margin ~20.9%; adj. EBITDA ~$88.8M (~12.5% of revenue).
At a glance
B+ balance sheet — decent shape, but not bulletproof
149.1x trailing p/e — distorted while GAAP EPS is near zero
10.5% return on capital — modest, not elite
$1.25 fy2027 eps est
$4B fy2029 rev est
xvary composite: 55/100 — below average
What they do
Legence designs, installs, and maintains the guts inside complex buildings that cannot afford to fail.
Legence sells pain avoidance. If your lab, hospital, or data-heavy building goes down, your day gets expensive fast. In Q3 2025, Installation & Maintenance was ~70% of consolidated revenue — the install/maintenance engine is the dominant mix in the latest quarter.
How they make money
~$1.81B
nine-month revenue (ended Sep 30, 2025) · Q3 2025 alone ~$708M
Installation and Maintenance (Q3 2025)
~$496M
+35% vs. prior year
Engineering and Consulting (Q3 2025)
~$212M
+9.5% vs. prior year
The products that matter
installs and maintains building systems
Installation & Maintenance
~$496M · ~70% of Q3 revenue
this is the center of gravity. Q3 2025 segment revenue was ~$496M (~70% of consolidated ~$708M) — gross margin at the segment level was ~16.3% that quarter, so execution and mix here move the consolidated print.
largest segment
designs and advises on system projects
Engineering & Consulting
~$212M · ~30% of Q3 revenue
still meaningful at ~$212M in Q3, with segment gross margin ~31.7% — it grows slower than I&M but is not the main drag on the consolidated growth rate in Q3.
execution watch
Key numbers
149.1x
trailing p/e
Trailing P/E is huge because GAAP EPS is near zero — valuation here is an adjusted-EBITDA / growth story until GAAP earnings normalize.
~4.7%
operating margin
Nine months ended Sep 2025 GAAP operating margin (~$85M income from operations on ~$1.81B revenue). Adj. EBITDA margin was ~11.7% same period — management and screens often focus on the latter.
10.5%
return on capital
Return on capital (profit earned on the money used in the business → how efficiently management turns dollars into earnings → 10.5% is okay, not elite) keeps this from being a quality no-brainer.
$813M
long-term debt
Long-term debt ~$813M on the Sep 30, 2025 balance sheet; company cited total debt ~$836M post-IPO paydown. Net debt ~$650M and net leverage ~2.4× LTM adj. EBITDA per release.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- long-term debt ~$813M long-term (Sep 30, 2025) · total debt ~$836M cited
- net profit margin ~−1.5% nine months 2025 (GAAP) — net loss attributable / revenue
- return on equity not meaningful yet — recent IPO + GAAP losses distort ROE
B+ — IPO improved liquidity; leverage is still real (net leverage ~2.4× adj. EBITDA per company).
Total return vs. market
Return history isn't available for LGN right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Q3 2025 revenue ~$708M (+26% vs. prior year); GAAP diluted EPS ~$(0.02) (miss vs ~$0.03 est).
Nine months 2025 revenue ~$1.81B (+~17% vs. prior year) with net loss attributable ~$(27)M — GAAP is noisy with interest, D&A, and IPO-related items. Q3 gross margin ~20.9%; adj. EBITDA ~$88.8M (~12.5% of revenue).
~$708M
Q3 revenue
$(0.02)
Q3 GAAP EPS
20.9%
Q3 gross margin
the number that mattered
Adj. EBITDA ~$88.8M in Q3 — the market is underwriting cash earnings power while GAAP EPS still prints a small loss.
-
legence corp. is building a public-market track record after its september 2025 ipo.the san jose-based engineering and maintenance company, which made its initial public offering this past september, recently published its first set of quarterly financial results.
-
the figures suggest rapid expansion of legence's business across a number of high-demand sectors.
-
indeed, third-quarter revenue of $708 million surged by around 26% from last year's pro forma level.growth was led by the larger installation and maintenance unit, where the segment-level margin was also higher.
-
engineering & consulting grew ~9.5% in q3, slower than installation & maintenance, with modest gross-margin pressure.in all, Q3 adj. EBITDA ~$88.8M (~12.5% margin) is the cleaner profitability read while GAAP EPS was still ~$(0.02).
-
strategic activities are already well underway at the newly public company.the nov 2025 release announced a definitive agreement to acquire bowers for total consideration of ~$475M (cash, debt, and equity), expected to close Q1 2026 — verify final terms in subsequent filings. in december, blackstone indicated a secondary of ~8M shares. expect capital structure to move materially vs the Q3 2025 snapshot.
source: Legence Q3 2025 release (Nov 14, 2025)
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the risk is specific: LGN has to prove a newly public acquisition story can turn $708M quarters into consistent profit, not just bigger revenue.
med
profit still has not caught up to growth
Revenue grew ~26% in Q3 vs. prior year, but nine-month GAAP net income margin was about −1.2% per the release — attributable net loss / revenue is closer to ~−1.5%.
At 149.1x trailing earnings, even a small stumble in profit can compress the multiple fast.
med
Bowers has to integrate cleanly
Nov 2025 definitive agreement: ~$475M total consideration for Bowers (cash, debt, equity), expected close Q1 2026 — integration risk starts after closing, not on the press release.
If integration drags on margins or cash generation, the deal will look more expensive than the deck slides suggested.
med
secondary stock sales can cap upside
Blackstone sold about 8M shares in a december secondary. Extra stock supply matters for a name with a short trading history and a valuation that already assumes better days ahead.
Even good quarters can get muted if the market is still digesting a large seller.
med
the public-company record is still thin
LGN only came public in september 2025. You do not have years of clean reported cadence to judge how resilient this model is across cycles.
That makes every earnings print more volatile for the stock and more important for your thesis.
A business with ~−1.5% GAAP net margin on nine-month revenue, ~$813M long-term debt, and a ~$475M Bowers ticket (pending close) does not get many free misses.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
Q4 and full-year 2025 report
March 27, 2026 is the next big proof point. Consensus sits at $0.07 EPS on $626.5M revenue. More important than the headline is whether margins look cleaner.
metric
net margin turning positive
The stock can live with a rich multiple only if GAAP net margin climbs out of negative territory. You do not need perfection — you need progress on interest, amortization, and tax noise.
segment mix
installation carrying the load
Installation & Maintenance was ~70% of Q3 revenue and led growth. If that segment slows before engineering consulting reaccelerates, the story gets less forgiving.
risk
post-deal debt and share count
Watch how Bowers (~$475M announced consideration), the december secondary, and updated debt terms flow through share count, leverage, and per-share earnings.
Analyst rankings
risk profile
average
risk rank 3 — typical risk profile — neither especially safe nor risky.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 83 buyers vs. 20 sellers in 4q2025. total institutional holdings: 72.4M shares.
source: institutional data
Price targets
3-5 year target range
$50
$75
$52.20
current price
$62
target midpoint · +20% from current · 3-5yr high: $75 (+45% · 9% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive